Last updated on November 2019

Autologous Cord Blood Cell Therapy for Neonatal Encephalopathy


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Hypoxic Brain Damage | Neonatal Encephalopathy
  • Age: - 1 Years
  • Gender: Male or Female

Inclusion Criteria:

Infants are eligible if they meet all the following inclusion criteria except 4.

  1. 36 weeks gestation
  2. Either a 10-minute Apgar score 5, continued need for resuscitation for at least 10 minutes, or severe acidosis, defined as pH <7.0 or base deficit 16 mmol/L in a sample of umbilical cord blood or any blood during the first hour after birth
  3. Moderate to severe encephalopathy (Sarnat II to III)
  4. A moderately or severely abnormal background amplitude-integrated EEG (aEEG) voltage, or seizures identified by aEEG, if monitored
  5. Up to 24 hours of age
  6. Autologous umbilical cord blood available to infuse within 3 days after birth
  7. A person with parental authority must have consented for the study.

Exclusion Criteria:

  1. Known major congenital anomalies, such as chromosomal anomalies, heart diseases
  2. Major intracranial hemorrhage identified by brain ultrasonography or computed tomography
  3. Severe growth restriction, with birth-weight less than 1800 g
  4. Severe infectious disease, such as sepsis
  5. Hyperkalemia
  6. Outborn infants (Infants born at hospitals other than the study sites)
  7. Volume of collected cord blood <40 ml
  8. Infants judged critically ill and unlikely to benefit from neonatal intensive care by the attending neonatologist

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.